Patients & Caregivers
Erdheim-Chester Disease Treatment Gets FDA Priority Review and Breakthrough Therapy Designation
The FDA accepted a supplemental New Drug Application and granted Priority Review for Zelboraf, a therapy for Erdheim-Chester disease with a BRAF V600 mutation.
FDA Approves First Treatment for Chronic Graft Versus Host Disease
TheFDA has approved Imbruvica (ibrutinib) for treating adults with chronic graft versus host disease (cGVHD) after failure of one or more treatments.
FDA Approves Idhifa (enasidenib) for Subset of AML Patients
The FDA approved Idhifa (enasidenib) for treating patients with relapsed or refractory AML who have mutations in their IDH2 gene.
Shopping to Support Ovarian Cancer Research
This Saturday, proceeds from shopping on QVC will go towards Ovarian Cancer Research Fund Alliance (OCRFA).
Josh Brolin Is Having Fun Helping the Rare Disease Community
Proceeds from the sales will go to St. Jude Children's Research Hospital and the Epidermolysis Bullosa Medical Research Foundation.
McCain Back at Work 10 Days after Brain Surgery
Just 10 days after undergoing surgery to remove a tumor in his brain, Arizona Senator John McCain is back at work in Washington D.C.
Government Begins Study to Test Targeted Therapies in Childhood Cancer
Pediatric MATCH is enrolling children and adolescents with solid tumors who have progressed either during or after standard therapy.
Senator John McCain Has Brain Cancer
Glioblastoma is the same type of cancer that the late Senator Ted Kennedy had.
Blincyto Gets FDA Full Approval to Treat ALL in Adults and Children
Adults with relapsed or refractory ALL generally have a poor prognosis with a median survival time of 3 to 5 months.
Napoleon and Hereditary Cancer
The emperor often talked about cancer and prior to his death, he demanded an autopsy be performed and his stomach be examined.
<< Prev Page
Next Page >>
STRATEGIC ALLIANCE PARTNERSHIP PROGRAM >
Familial Chylomicronemia Syndrome
MJH ASSOCIATES >
Specialty Pharmacy Times
Terms & Conditions
Copyright © RareDR 2013-2017 Rare Disease Communications. All Rights Reserved.